Medivir AB (LTS:0GP7) Days Payable: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GP7 Medivir AB LTS:0GP7
59 GF Score
Price kr1.72
GF Value kr1.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Days Payable?

Medivir AB's average Accounts Payable for the three months ended in Jun. 2026 was kr0.00 Mil. Medivir AB's Cost of Goods Sold for the three months ended in Jun. 2026 was kr22.20 Mil. Hence, Medivir AB's Days Payable for the three months ended in Jun. 2026 was 0.00.

The historical rank and industry rank for Medivir AB's Days Payable or its related term are showing as below:

During the past 13 years, Medivir AB's highest Days Payable was 1074.02. The lowest was 1074.02. And the median was 1074.02.

LTS:0GP7's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.24
* Ranked among companies with meaningful Days Payable only.

Medivir AB's Days Payable stayed the same from Jun. 2025 () to Jun. 2026 (). stayed the same

Medivir AB Days Payable Historical Data

* Premium members only.

The historical data trend for Medivir AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Days Payable Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.01 29.25 37.75 40.11 33.77

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only

LTS:0GP7 vs VRTX, REGN, MRNA: Days Payable Comparison

For the Biotechnology subindustry, Medivir AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Medivir AB's Days Payable falls into.


LTS:0GP7
59GF Score
Medivir AB LTS:0GP7
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Medivir AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (12.067 + 6.278) / 2 ) / 99.133*365
=9.1725 / 99.133*365
=33.77

Medivir AB's Days Payable for the quarter that ended in Jun. 2026 is calculated as:

Days Payable (Q: Jun. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2026 ) + Accounts Payable (Q: Jun. 2026 )) / count ) / Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=( (0 + 0) / 1 ) / 22.2*365 / 4
=0 / 22.2*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Medivir AB (LTS:0GP7) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.72 is trading 38.5% above its estimated GF Value™ of kr1.24. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for LTS:0GP7:

  • Days Payable:
  • GF Value™: kr1.24 vs. price of kr1.72 (38.5% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
59GF Score

Get the complete analysis for LTS:0GP7

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.72
Price
kr1.24
GF Value